Clinical TrialAug 13, 2026, 04:01 PM
ProMIS Neurosciences PMN310 Phase 1b AD Trial Shows Positive Safety
AI Summary
ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 for early Alzheimer's disease, showing zero cases of ARIA-E and consistent declines in key biomarkers. The company reported $53.4 million in cash and short-term investments as of June 30, 2026, providing funding through 2027. The net loss for Q2 2026 was $11.7 million, or $1.28 per share, with 12-month topline results from PRECISE-AD expected in Q1 2027.
Key Highlights
- PMN310 Phase 1b interim data showed zero ARIA-E cases across all participants.
- Plasma pTau217 declined approximately 15% and CSF MTBR-tau243 declined approximately 13.3%.
- Cash and short-term investments totaled $53.4 million as of June 30, 2026.
- Cash runway extends through 2027, beyond anticipated Q1 2027 topline readout.
- Net loss for Q2 2026 was $11.7 million, or $1.28 per share.
- 12-month topline PRECISE-AD results are expected in the first quarter of 2027.
- PMN310 was granted Fast Track designation by the USFDA in July 2025.
Price Impact
More from PMN